Home / News / Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s

Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s

May 28, 2023May 28, 2023

New hemostasis analysis system allows clinicians to better maintain a patient's coagulation equilibrium using unique all-in-one design

News provided by

01 Jun, 2016, 08:00 ET

Share this article

SAN DIEGO and BRAINTREE, Mass., June 1, 2016 /PRNewswire/ -- Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category.

The award recognizes the TEG® 6s hemostasis analyzer, a compact diagnostic instrument that provides clinicians with rapid, comprehensive and accurate identification of a patient's hemostasis condition in a laboratory or point-of-care setting. The Good Design Award is presented annually by Good Design Australia and recognizes excellence in design, innovation and creativity across a broad range of industries and design disciplines at a national and international level.

"As a tool that helps make better treatment decisions that lead to reduced risks, complications and costs, the TEG 6s system has been very well received by clinicians and laboratories in the U.S. and around the world," said Krista Thompson, Vice President of Hemostasis Management at Haemonetics. "This award acknowledges the unique design of the TEG 6s compared to traditional hemostasis testing. It also highlights the dedication and innovation of the teams at Haemonetics, Invetech and Coramed who were committed to developing better assessments for blood management so clinicians can make informed therapy decisions."

The TEG 5000 is currently being used in hundreds of hospitals globally and the TEG 6s, a key new product in a family of solutions offered by Haemonetics in its Hemostasis Management franchise, is anticipated to accelerate adoption. The TEG 6s analyzer features a compact, minimalist design and a refined user experience with innovations including a patented resonance and sensing algorithm. A complete picture of a patient's hemostasis can be developed with one test containing up to four assays. The TEG 6s system includes the TEG 6s analyzer, all-in-one patented test cartridges, and the TEG Manager™ software, allowing clinicians to assess both coagulation and the effects of antiplatelet therapy using one device. The all-in-one cartridge also provides rapid, comprehensive and accurate test results without complicated manual processing, for greater throughput and more consistent results.

"This award is further acknowledgement of Invetech's ability to enable the important and complex work of emerging medical technology developers by providing innovation, creativity and engineering excellence," said Rob Danby, global vice president of diagnostics at Invetech. "We are glad to be part of the TEG 6s design and manufacturing team and look forward to ongoing opportunities to collaborate and support better quality of care and clinical success stories."

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative technology and software solutions for their customers. The company's comprehensive portfolio of integrated devices and information management offers solutions for hospitals, plasma and blood collectors, and patients around the world. Collectively they help improve patient care, improve patient safety, and reduce costs. To learn more about Haemonetics, visit

Haemonetics Media Contact:Sandra Jesse, EVP, Chief Legal OfficerHaemoneticsPhone: 781-356-9253[email protected]

About Coramed Technologies

Coramed Technologies was launched in 2008 by the founders of Haemoscope Corporation, creators of the currently marketed TEG® 5000 hemostasis analyzer. While the TEG 5000 is a successful, industry-leading instrument, it can only be used in a laboratory or hospital setting. Coramed has developed new CORA® technology that has led to a smaller, easier-to-use device that can be operated virtually anywhere. Coramed received FDA marketing clearance of initial devices incorporating CORA technology in 2015.

About Invetech

Invetech has been creating breakthrough products and custom automation systems for more than 30 years. With experience drawn from more than 5000 projects globally, Invetech partners with global leaders in industry to deliver product design and development, contract manufacturing and custom automation services. The company has experience in a broad range of market sectors including cell therapy production automation systems, laboratory diagnostics, point of care diagnostics, life sciences, industrial and consumer products. To learn more about Invetech, visit

Invetech Media Contact:Bill BerryBerry & Company Public RelationsPhone: 212-253-8881[email protected]

Photo - Logo -

SOURCE Invetech